Complications of nephrotic syndrome

Se Jin Park, MD¹, Jae Il Shin, MD²

¹Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, ²The Institute of Kidney Disease, Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea

Nephrotic syndrome (NS) is one of the most common glomerular diseases that affect children. Renal histology reveals the presence of minimal change nephrotic syndrome (MCNS) in more than 80% of these patients. Most patients with MCNS have favorable outcomes without complications. However, a few of these children have lesions of focal segmental glomerulosclerosis, suffer from severe and prolonged proteinuria, and are at high risk for complications. Complications of NS are divided into two categories: disease-associated and drug-related complications. Disease-associated complications include infections (e.g., peritonitis, sepsis, cellulitis, and chicken pox), thromboembolism (e.g., venous thromboembolism and pulmonary embolism), hypovolemic crisis (e.g., abdominal pain, tachycardia, and hypotension), cardiovascular problems (e.g., hyperlipidemia), acute renal failure, anemia, and others (e.g., hypothyroidism, hypocalcemia, bone disease, and intussusception). The main pathomechanism of disease-associated complications originates from the large loss of plasma proteins in the urine of nephrotic children. The majority of children with MCNS who respond to treatment with corticosteroids or cytotoxic agents have smaller and milder complications than those with steroid-resistant NS. Corticosteroids, alkylating agents, cyclosporin A, and mycophenolate mofetil have often been used to treat NS, and these drugs have treatment-related complications. Early detection and appropriate treatment of these complications will improve outcomes for patients with NS.

Key words: Nephrotic syndrome, Complications, Proteinuria, Child

Introduction

Nephrotic syndrome (NS) is classically defined as massive proteinuria (>40 mg/m²/hr), hypoalbuminemia (<2.5 g/dL), generalized edema, and hyperlipidemia in most cases¹. The majority of nephrotic children have minimal change lesions, and these will either remit spontaneously within three years (two-thirds of the cases) or have earlier remission without complications following treatment with corticosteroids (CS) or cytotoxic agents (95%)². However, the minority of children who have lesions of focal segmental...
glomerulosclerosis and severe and prolonged proteinuria are at high risk for complications. In these children, full nephrotic syndrome may progress to renal failure and even to dialysis, ultimately requiring renal transplantation.

Complications in NS may occur as a part of the disease itself or as a consequence of drug treatment. The loss of plasma proteins in the urine causes complications of NS as a direct result of the changing protein concentrations in the plasma or as a secondary result of altered cellular function\(^3\). Disease-associated complications include infections, thromboembolism, cardiovascular disease, hypovolemic crisis, anemia, and acute renal failure. CS, alkylating agents, calcineurin inhibitors, and mycophenolate mofetil (MMF) are usually related to the complications of long-term therapy in nephrotic children. Here, we focus on the complications occurring in children with NS (Table 1).

### Nephrotic syndrome-related complications

#### 1. Infections

Patients with NS are at increased risk for infections. Although the incidence of infections in NS has decreased in advanced countries, they are still a major problem in developing countries\(^4\). Sepsis remains one of the main causes of death in children with NS\(^5\). Children treated with cytotoxic drugs have a higher clinical infection rate than those treated only with prednisolone\(^6\). In children with NS, *Streptococcus pneumoniae* is known to be the most important organism in primary peritonitis. However, other organisms such as \(\beta\)-hemolytic streptococci, *Haemophilus* and Gram-negative bacteria are also frequently found\(^7\). Cellulitis is also the result of \(\beta\)-hemolytic streptococci or a variety of Gram-negative bacteria.

Several immunological factors such as low serum immunoglobulin G concentrations, factor B and factor I in the alternative pathway components, transferrin, depressed T-cell function, and physiological factors such as fluid collection in cavities and dilution of local humoral defenses by edema may play a major role in the susceptibility of nephrotic patients to infection\(^8\).

Pneumococcal vaccines against capsular antigens is recommended for all children with NS\(^9\), but vaccination should be administered when the treatment with high doses of CS or with cytotoxic therapy is discontinued. Nephrotic children taking high-dose CS or other immunosuppressive agents within three months of their use are at risk of varicella infection, requiring varicella zoster immunoglobulin treatment within 72 hours of exposure and intravenous acyclovir during active varicella zoster infection\(^10\).

#### 2. Thromboembolism

NS is a well-known risk factor for arterial or venous thromboembolism (TE), and patients with severe proteinuria have a 3.4-fold higher risk of venous TE\(^11\). It is also known that there is higher risk of TE in steroid-resistant NS than in steroid-sensitive NS\(^12\).

Thrombosis may arise in NS from loss of proteins involved in the inhibition of systemic hemostasis, increased synthesis of prothrombotic factors or by local activation of the glomerular hemostasis system\(^13\). The predisposing factors of TE in NS are as follows\(^14,15\): 1) abnormalities in platelet activation and aggregation, 2) activation of the coagulation system; increased synthesis of factors V, VII, VIII, X, von Willebrand factor, fibrinogen, and \(\alpha_2\)-macroglobulin accumulation, 3) decreased endogenous anticoagulants; antithrombin III, protein C, protein S, and tissue factor pathway inhibitor, 4) decreased activity of fibrinolytic system; plasminogen,

### Table 1. Major Complications of the Nephrotic Syndrome

| Disease-related complications | Drug-related complications |
|------------------------------|----------------------------|
| Infections: primary peritonitis, sepsis, cellulitis, chickenpox | Corticosteroids: obesity, growth retardation, hypertension, osteoporosis, cataract, glaucoma, and behavioral changes, etc. |
| Venous thromboembolism, pulmonary embolism | Alkylating agents: bone marrow suppression, alopecia, nausea, vomiting, hemorrhagic cystitis, infections, infertility, secondary malignancy |
| Abdominal pain, tachycardia, hypotension | Cyclosporin A: nephrotoxicity, neurotoxicity, gingival hyperplasia, hirsuitism, and hypertension, etc. |
| Hyperlipidemia, vasculitis | Mycophenolate mofetil: nausea, vomiting, bone marrow suppression |
| Anemia | Tacrolimus: diabetes, hypertension, nephrotoxicity, tremor, headache, etc. |
| Acute renal failure | Rituximab: bronchospasm, myocardial infarction, progressive multifocal leukoencephalopathy, and reactivation of viruses |
| Hypothyroidism, hypocalcemia, bone disease | Hormonal and mineral alterations: hypothyroidism, hypocalcemia, bone disease |
| Table 1. Major Complications of the Nephrotic Syndrome | Table 1. Major Complications of the Nephrotic Syndrome |
the precursor for plasmin, and the imbalance of two major regulators of plasmin formation, plasminogen activator inhibitor-1 and tissue plasminogen activator\(^{20}\), 5) changes in the glomerular hemostatic system, 6) intravascular volume depletion, and 7) exposure to CS and diuretics\(^{17,28}\).

Doing arterial punctures should be avoided in nephrotic children due to the risk of arterial thrombosis. Gross hematuria with or without acute renal failure may suggest renal vein thrombosis in nephrotic children, which needs Doppler ultrasonography or magnetic resonance angiography\(^{29}\). Particularly, when nephrotic patients appear to have tachypnea and dyspnea, we should keep in mind the high probability of pulmonary embolism and perform ventilation-perfusion lung scanning or pulmonary angiography immediately\(^{20}\).

### 3. Cardiovascular complications

An increased risk of cardiovascular disease exists in patients with NS because of hyperlipidemia, increased thrombogenesis, and endothelial dysfunction\(^{29}\). Hypercholesterolemia is strongly associated with severity of hypoalbuminemia, and persistent proteinuria or renal insufficiency also contributes to cardiovascular disease\(^{22}\).

There is little or no risk of cardiovascular disease in children with MCNS who are responsive to CS because hyperlipidemia is intermittent and of short duration. The risk of premature atherosclerosis is increased due to hyperlipidemia. The duration of nephrotic hyperlipidemia appears to be critical to initiating vascular damage, and patients with unremitting proteinuria and hypoalbuminemia are the most at risk\(^{20}\).

Very low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and lipoprotein (a) are elevated in children with long-standing and frequently relapsing NS\(^{20}\). Elevated VLDL and LDL should place patients at increased risk for developing atherosclerosis. Hyperlipidemia contributes to the development of glomerular and interstitial renal disease. Endothelial damage from hyperlipidemia may favor influx of lipoprotein into the mesangium, leading to proliferation and sclerosis\(^{22}\).

Therapy with lipid-lowering drugs, hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, should be given with extreme caution in children as it remains controversial. Although Prescott et al.\(^{24}\) reported that lowering cholesterol levels during childhood might reduce the risk for atherosclerotic changes and suggested short-term safety and efficacy of HMG-CoA reductase inhibitors, others showed that excessive free lipid-lowering drugs with low albumin levels may affect proximal muscle pain and malaise even at a normal dose\(^{25,26}\). Therefore, more prospective controlled studies in children are needed in the future to evaluate the efficacy and safety of lipid-lowering drugs.

### 4. Hypovolemic crisis

Hypovolemic shock is one of the attentive presentations in NS\(^{27}\). Risk factors for hypovolemic crisis include severely depressed albumin levels, high dose diuretics, and vomiting. The clinical manifestations are tachycardia, cold extremities, poor capillary refill, and moderate to severe abdominal pain, and laboratory tests may show elevated hematocrit and uric acid levels.

It is useful to measure urinary sodium (\(U_{\text{Na}}\)) excretion or fractional excretion of sodium (FENa) when evaluating physical volume status. Donckerwolcke et al.\(^{28}\) found a better correlation between log aldosterone and urinary potassium / urinary potassium + urinary sodium (\(U_{K} / U_{\text{Na}} + U_{K}\)) ratio than with other parameters measuring renal potassium and sodium handling. In patients with renal sodium retention (FENa: <0.5%), \(U_{K} / U_{\text{Na}} + U_{K}\) ratio of higher than 0.6 (\(U_{K} / U_{\text{Na}} + U_{K}\) >60%) identifies patients with increased aldosterone levels and functional hypovolemia\(^{29}\).

This index may therefore be used to assess which patients will benefit from intravenous normal saline (20 mL/kg over 1 to 2 hours) or albumin administration at maximum dose of 1 g/kg over 3 to 5 hours with blood pressure monitoring\(^{29}\). The administration of albumin is not routinely given to all patients in relapse and may be dangerous in children who are not volume depleted due to the risk of pulmonary edema.

### 5. Anemia

Mild anemia is observed on occasion in patients with NS. Anemia is usually microcytic and hypochromic, typical of iron deficiency, but is resistant to therapy with iron because of large loss of serum transferrin in the urine of some nephrotic patients\(^{30}\). Vaziri\(^{31}\) reported some data on the metabolism and regulation of erythropoietin (EPO) and transferrin, which are essential for erythropoiesis in nephrotic children.

Urinary loss of EPO causes EPO-deficiency anemia and transferrinuria, and increased transferrin catabolism induces hypotranferrinemia and iron-deficiency anemia in some cases. Subcutaneous administration of recombinant EPO and iron supplementation can be used for the treatment of EPO- and iron-deficiency anemia, respectively\(^{32}\). However, correction of the underlying proteinuria will be the ideal approach to reversing these complications.

### 6. Acute renal failure

Acute renal failure (ARF) is an uncommon but alarming complication of NS\(^{33}\). When massive proteinuria develops and the levels
of albumin are profoundly decreased, the circulating volume in the plasma is reduced to produce circulatory collapse or pre-renal uremia, usually of mild degree. However, much less commonly, ARF that is unresponsive to volume replacement and aggressive diuretic therapy may be seen in certain forms of NS without the features of volume depletion. This may be due to severe disturbance in visceral epithelial cells that results in almost total obliteration of the slit pores and severe reduction in surface area for filtration. With severe proteinuria, occlusion of the distal nephron lumina from cast formation or extratubule compression from renal interstitial edema may result in an increase in proximal tubular pressure, leading to a fall in glomerular filtration rate.

ARF is usually precipitated by sepsis, radiocontrast agents, acute tubular necrosis from nephrotoxic antibiotics and non-steroidal anti-inflammatory agents. If renal failure persists for more than a few days, dialysis may be necessary for complete recovery.

7. Edema
Edema is often observed in nephrotic children and where tissue pressure is low. Ascites and pericardial effusions frequently occur, but pericardial effusion is rare unless cardiac function is abnormal. Edema is caused by increased glomerular permeability and hypoalbuminemia, resulting in decreased plasma oncotic pressure and functional hypovolemia. These stimulate secondary sodium retention by the kidney.

Treatment of edema consists of dietary sodium restriction and judicious use of loop-acting diuretics such as furosemide and bumetanide. Hyperoncotic salt-poor albumin and furosemide may be administered in cases of severe and refractory edema.

8. Hormonal, mineral alterations and intussusceptions
Urinary loss of hormone-binding proteins contributes to various hormonal abnormalities in patients with NS. While thyroid function tests are in the normal range in most nephrotic patients, the mean values for triiodothyronine (T3) and thyroid-binding globulin (TBG) are lower than those in non-NS children because of a significant increase in urinary excretion of T3, T4 and TBG. Routine thyroid screening and early replacement therapy of thyroid hormone are necessary for infants with severe NS and clinical hypothyroidism.

Hypocalcemia in NS is also attributed to the decreased albumin level, which results in reduced bound and ionized calcium in 50 to 80% of NS cases. Children with NS often have hypocalcemia due to decreased gastrointestinal absorption of calcium and increased renal tubular reabsorption of calcium. These suggest the possibility of an abnormality in vitamin D metabolism. The abnormalities are due to increased filtration of vitamin D metabolites bound to vitamin D-binding globulin. However, bone disease is rarely shown in NS patients, and therefore, routine treatment with vitamin D is not recommended. Nevertheless, special concern should be given to subclinical mineral bone disorder like secondary hyperparathyroidism.

Intussusceptions can occur within the ileocolic junction and the small intestines in patients with NS, causing acute abdominal pain. They are caused by a combination of patches of bowel wall edema and peristaltic incoordination. Cho et al. reported a case involving reversal of intussusceptions associated with nephrotic syndrome by infusion of albumin.

**Adverse effects of long-term drug therapy**

1. Corticosteroids
CS have reduced the NS mortality rate to around 3%. However, CS have well-recognized potentially serious adverse effects such as cushingoid features, obesity, growth retardation, hypertension, osteoporosis, cataracts, impaired glucose metabolism, dyslipidemia, emotional deprivation, behavioral changes, and avascular necrosis of the femoral head.

Two major causes of growth retardation in patients with NS are the loss of insulin-like growth factors (IGFs) and/or IGF-binding proteins (IGFBPs) and CS therapy. Several reports have suggested that there are changes in serum levels of IGFs and IGFBPs among nephrotic children. CS induce overt elevation of serum IGF-1 levels, which results in the potential development of IGF resistance, one of the main factors responsible for persistent growth retardation. Bone maturation and linear growth are delayed and arrested by long-term, high-dose CS therapy, particularly when the dosage exceeds 0.5 mg/kg/day. Therefore, the initial dose should be low in the range of 0.2 to 0.4 mg/kg (5 to 15 mg/m²) per dose for treatment maintenance.

Jeon et al. reported that alternate-day steroid therapy, as a single morning dose, does not affect growth but may lead to decrement of serum vitamin D3 levels and bone mineral density in children with NS. The best way to avoid growth retardation is to stop unnecessarily extended courses of therapy with high doses of CS. To reduce the complications associated with CS therapy, the following strategies may be helpful:

a. Adrenal suppression: alternate-day steroid therapy.

b. Impairment of statural growth: CS-sparing agents, and growth hormone therapy.

c. Osteoporosis: Calcium, vitamin D supplementation, and use of steroid-sparing protocols.

d. Peptic ulceration: H2 blockers.
Complications of nephrotic syndrome

2. Cyclophosphamide (CPM)

Alkylation agents impair DNA transcription by attaching alkyl chains to purine bases. Latta et al.\(^5\) addressed the side effects of alkylating agents, including early complications of bone marrow suppression, alopecia, gastrointestinal upset, hemorrhagic cystitis, and infections, and late complications of possible malignancies and impaired fertility, especially in males. There is a dose-dependent relationship between sperm counts and the cumulative dose of CPM.\(^5\) To avoid gonadal toxicity, CPM should not be used for more than 12 weeks (2 mg/kg, single oral dose) and should be withheld if the white blood cell count is less than 5,000/mm\(^3\) during CPM use. High fluid intake is recommended to elude hemorrhagic cystitis during the use of CPM.

3. Cyclosporin A (CsA)

CsA is an immunosuppressive fungal metabolite that acts by modifying T-cell function and inhibiting the release of interleukin-2 from activated T helper cells.\(^6\) Long-term use of CsA causes reduced renal function, gingival hyperplasia, hirsuitism, hypertension, hyperkalemia, and encephalopathy.\(^5\) CsA-induced tubulointerstitial lesions are found in 30 to 40% of children who have received CsA for more than 12 months.\(^5\) Several publications have shown risk factors for CsA complications, such as the long duration of CsA treatment, a high CsA trough level, and a younger age at the start of CsA treatment.\(^5\) Therefore, the lowest effective dose of CsA is recommended for the maintenance treatment in nephrotic children, with slow tapering over one year to 1 to 3 mg/kg/day. Yang et al.\(^5\) found that the combined treatment of CsA and MMF did not prevent the development of chronic CsA nephrotoxicity, but MMF treatment after CsA withdrawal improves chronic CsA nephrotoxicity. Recently, Hara et al.\(^6\) also reported protective effects of Mizoribine on CsA nephropathy in rats.

4. Others

Complications of MMF include gastrointestinal disturbances, bone marrow suppression, and headache, requiring dose reduction or even withdrawal.\(^5\) Tacrolimus is a calcineurin inhibitor that has similar action to CsA but can have several side effects, such as hypertension, abnormal renal function, tremor, muscle cramps, hyperkalemia, hypophosphatemia, leukopenia, and hyperglycemia. Levamisole, the antihelminthic agent, can be used in steroid-dependent patients, but is ineffective as a permanent therapy for NS. Levamisole may have the minor side effects of leukopenia, gastrointestinal effects, and vasculitis, but no important side effects were reported.\(^6\) Rituximab has recently been introduced and may be applied to steroid-dependent or refractory nephrotic syndrome.\(^6\) Complications of Rituximab include life-threatening bronchospasm, myocardial infarction, progressive multifocal leukoencephalopathy, and reactivation of viruses such as cytomegalovirus and hepatitis B virus.\(^6\)

Conclusions

The complications of the NS can be divided into two categories, disease-associated and treatment-related. When we treat children with NS, it is important to start with early identification and appropriate treatment for acute complications. Regular examinations and monitoring for chronic complications will improve outcomes for children with NS.

References

1. Ulinski T, Aoun B. Pediatric idiopathic nephrotic syndrome: treatment strategies in steroid dependent and steroid resistant forms. Curr Med Chem 2010;17:847-53.
2. Schrier RW, Gottschalk CW. Diseases of the Kidney. 4th ed. Boston: Little, Brown, 1988;1749, 1899.
3. Davison AM, Cameron JS, Grunfeld JP, Ponticelli C, Ritz E, Winears CG, et al. Oxford textbook of clinical nephrology. 3rd ed. New York: Oxford University Press, 2005;421.
4. Gulati S, Kher V, Gulati K, Arora P, Gujral R. Tuberculosis in childhood nephrotic syndrome in India. Pediatr Nephrol 1997;11:695-8.
5. Gorenshek MJ, Lebel MH, Nelson JD. Peritonitis in children with nephrotic syndrome. Pediatrics 1988;81:849-56.
6. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001;16:271-82.
7. Tain YL, Lin G, Cher TW. Microbiological spectrum of septicemia and peritonitis in nephrotic children. Pediatr Nephrol 1999;13:835-7.
8. Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders, 2007;2193-4.
9. Tejani A, Fikrig S, Schiffman G, Gurumurthy K. Persistence of protective pneumococcal antibody following vaccination in patients with the nephrotic syndrome. Am J Nephrol 1984;4:32-7.
10. Alpay H, Yildiz N, Onar A, Temizer H, Ozcan S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2002;17:181-3.
11. Kato S, Chernyavsky S, Tokita JE, Shimada YJ, Homel P, Rosen H, et al. Relationship between proteinuria and venous thromboembolism. J Thromb Thrombolysis 2010;30:281-5.
12. Ulinski T, Guigonis V, Bauder-Bonneville V, Auber F, Garrette K, Bensman A. Mesenteric thrombosis causing short bowel syndrome in nephrotic syndrome. Pediatr Nephrol 2003;18:1295-7.

13. Cade R, Spooner G, Juncos L, Fuller T, Raulerson D, et al. Chronic renal vein thrombosis. Am J Med 1977;63:387-97.

16. Lau SO, Tkachuck JY, Hasegawa DK, Edson JR. Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. J Pediatr 1980;96(3 Pt 1):390-2.

17. Ozsoylu S, Strauss HS, Diamond LK. Effects of corticosteroids on coagulation of the blood. Nature 1962;195:1214-5.

18. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol 2004;19:744-8.

19. Witz M, Korzets Z. Renal vein occlusion: diagnosis and treatment. Isr Med Assoc J 2007;9:402-5.

20. Huang J, Yang J, Ding J. Pulmonary edema status in nephrotic syndrome. Intern Med 2011;50:551-5.

21. Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ. The reversal of intussusception associated with nephrotic syndrome by infusion of albumin. Pediatr Nephrol 2009;24:421-2.

22. Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J. Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr 1984;104:61-4.

23. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncostic pressure, and viscosity. N Engl J Med 1985;312:544-8.

24. Prescott WA Jr, Streetman DA, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 2004;38:2105-14.

25. Dong F, Zhou X, Pang N, Wei M. Effect of glucocorticoid treatment in nephrotic syndrome children on chronic glucocorticoid treatment. Curr Opin Rheumatol 2007;19:67-73.

26. Wang SJ, Tsau YK, Lu FL, Chen CH. Hypovolemia and hypovolemic shock in children with nephrotic syndrome. Acta Paediatr Taiwan 2000;41:179-83.

27. Matsumoto H, Miyaoka Y, Okada T, Nagaoka Y, Wada T, Gondo A, et al. Ratio of urinary potassium to urinary sodium and the potassium and edema status in nephrotic syndrome. Intern Med 2011;50:531-5.

28. Ellis D. Anemia in the course of the nephrotic syndrome secondary to transferrin depletion. J Pediatr 1977;90:953-5.

29. Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 2001;38:1-8.

30. Toubiana J, Schlager MH, Aoun B, Dunand O, Vitkevic R, Bensman A, et al. Therapy-resistant anaemia in congenital nephrotic syndrome of the Finnish type--implication of EPO, transferrin and transcobalamin losses. Nephrol Dial Transplant 2009;24:1338-40.

31. Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2003;18:1289-92.

32. Loh SC, Tkachuk JY, Hasegawa DK, Edson JR. Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. J Pediatr 1980;96(3 Pt 1):390-2.

33. Raji L, Keane WF, Leonard A, Shapiro FL. Irreversible acute renal failure in idiopathic nephrotic syndrome. Am J Med 1976;61:207-14.

34. Lowenstein J, Schacht RG, Baldwin DS. Renal failure in minimal change nephrotic syndrome. Am J Med 1981;70:227-33.

35. Vande Walle JG, Donckerwolcke RA. Pathogenesis of edema formation in the nephrotic syndrome. Pediatr Nephrol 2001;16:283-93.

36. Muranjan MN, Kher AS, Nadkarni UB, Kamat JR. Congenital nephrotic syndrome with clinical hypothyroidism. Indian J Pediatr 1995;62:233-5.

37. Goldstein DA, Haldimann B, Sherman D, Norman AW, Massry SG. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1981;52:116-21.

38. Sato KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med 1982;99:325-30.

39. Sato KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med 1982;99:325-30.

40. Zhou X, Loke KY, Pillai CC, How HK, Yoo KH, Hong YS, et al. The effect of steroid therapy on growth and bone density in children with nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH. Eur J Endocrinol 2001;144:237-43.

41. Dong F, Zhou X, Pang N, Wei M. Effect of glucocorticoid treatment on insulin like growth factor-I and its binding proteins in children with nephrotic syndrome. Pediatr Nephrol 2003;18:1289-92.

42. Grenda R, Webb NJ. Steroid minimization in pediatric renal transplantation: early withdrawal or avoidance? Pediatr Transplant 2010;14:661-7.

43. Vande Walle JG, Donckerwolcke RA. Pathogenesis of edema formation in the nephrotic syndrome. Pediatr Nephrol 2001;16:283-93.

44. Lowenstein J, Schacht RG, Baldwin DS. Renal failure in minimal change nephrotic syndrome. Am J Med 1981;70:227-33.

45. Abe T, Ichimaru N, Kakuta Y, Okami M, Imamura R, Isaka Y, et al. Therapy-resistant anaemia in congenital nephrotic syndrome of the Finnish type--implication of EPO, transferrin and transcobalamin losses. Nephrol Dial Transplant 2009;24:1338-40.

46. Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2003;18:1289-92.

47. Raji L, Keane WF, Leonard A, Shapiro FL. Irreversible acute renal failure in idiopathic nephrotic syndrome. Am J Med 1976;61:207-14.

48. Lowenstein J, Schacht RG, Baldwin DS. Renal failure in minimal change nephrotic syndrome. Am J Med 1981;70:227-33.

49. Vande Walle JG, Donckerwolcke RA. Pathogenesis of edema formation in the nephrotic syndrome. Pediatr Nephrol 2001;16:283-93.

50. Muranjan MN, Kher AS, Nadkarni UB, Kamat JR. Congenital nephrotic syndrome with clinical hypothyroidism. Indian J Pediatr 1995;62:233-5.

51. Goldstein DA, Haldimann B, Sherman D, Norman AW, Massry SG. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1981;52:116-21.

52. Sato KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Clin Med 1982;99:325-30.

53. Cho MH, Hwang HH, Choe BH, Kwon SH, Ko CW, Kim JY, et al. The reversal of intussusception associated with nephrotic syndrome by infusion of albumin. Pediatr Nephrol 2009;24:421-2.

54. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007;(4):CD001533.

55. Grenda R, Webb NJ. Steroid minimization in pediatric renal transplantation: early withdrawal or avoidance? Pediatr Transplant 2010;14:661-7.

56. Dong F, Ren J. Insulin-like growth factors (IGFs) and IGF-binding proteins in nephrotic syndrome children on glucocorticoid. Pharmacol Res 2003;48:319-23.

57. Zhou X, Loke KY, Pillai CC, How HK, Yap HK, Lee KO. IGFs and IGF-binding proteins in children with nephrotic syndrome. J Pediatr Nephrol Dial Transplant 2009;24:1338-40.

58. Muranjan MN, Kher AS, Nadkarni UB, Kamat JR. Congenital nephrotic syndrome with clinical hypothyroidism. Indian J Pediatr 1995;62:233-5.
52. Chishti AS, Sorof JM, Brewer ED, Kale AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 2001;38:754-60.

53. Bertani T, Perico N, Abbate M, Battaglia C, Remuzzi G. Renal injury induced by long-term administration of cyclosporin A to rats. Am J Pathol 1987;127:569-79.

54. Kim JH, Park SJ, Yoon SJ, Lim BJ, Jeong HJ, Lee JS, et al. Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. J Clin Pathol 2011;64:516-9.

55. Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002;61:1801-5.

56. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child 2006;91:666-70.

57. Yang CW, Ahn HJ, Kim WY, Li C, Kim HW, Choi BS, et al. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 2002;62:20-30.

58. Hara S, Umino D, Someya T, Fujinaga S, Ohtomo Y, Murakami H, et al. Protective effects of Mizoribine on Cyclosporine A nephropathy in rats. Pediatr Res 2009;66:524-7.

59. Aiyangar A, Rajput P, Shah BV. Mycophenolate induced diarrhoea. J Assoc Physicians India 2010;58:192-4.

60. De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients. Clin J Am Soc Nephrol 2011;6:690-4.

61. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007;356:2751-2.

62. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-98.